treating – Earlybirds Invest https://earlybirdsinvest.com Latest Crypto News Sat, 23 Aug 2025 22:10:25 +0000 en-US hourly 1 https://wordpress.org/?v=6.9.8 https://i0.wp.com/earlybirdsinvest.com/wp-content/uploads/2024/12/cropped-New-Project-2024-12-17T235703.455.png?fit=32%2C32&ssl=1 treating – Earlybirds Invest https://earlybirdsinvest.com 32 32 240146708 Stop treating tokens like payday buttons — they’re infrastructure https://earlybirdsinvest.com/stop-treating-tokens-like-payday-buttons-theyre-infrastructure/ https://earlybirdsinvest.com/stop-treating-tokens-like-payday-buttons-theyre-infrastructure/#respond Sat, 23 Aug 2025 22:10:25 +0000 https://earlybirdsinvest.com/stop-treating-tokens-like-payday-buttons-theyre-infrastructure/

The following is a guest post and opinion from Corey Billington, Co-Founder and CEO at Blubird.

Most token launches play out the same way. Founders spend weeks buried in spreadsheets, lawyers churn out disclaimers, and influencers start teasing “TGE soon.” Behind the scenes, though, private round investors are just waiting for cliffs to end so they can dump. Circulating supply spikes, token price tanks, and social media fills with threads about “unlock risk.”

Somewhere in the mess, we forget the obvious: tokens are infrastructure, not short-term fundraising tools.

I’ve worked with over 80 teams, and the same pattern keeps coming up. Founders rush to mint a token so they can raise without touching equity. Then they try to backfill utility into the product later — a strategy that rarely succeeds. That backwards approach is what leads to all the usual failures: oversized insider allocations, unlock schedules that make no sense, and “use cases” that no one actually uses.

At that point, every token purchase is just helping someone else cash out.

Why Raising First and Figuring It Out Later Breaks Everything

When your token’s main job is to raise money, you’re walking into two problems: legal risk and market damage.

On the legal side, if your token doesn’t have real utility from the start, it starts looking like a security — and the SEC isn’t known for nuance. You can call it a utility token, but the Howey Test doesn’t care about your pitch deck. And if you pair that with a fast emissions schedule and the token price crashes — don’t be surprised if frustrated holders come knocking.

But the real damage is strategic. Projects that treat the token like a fundraising shortcut almost never have a plan for what happens after launch. They end up building around cliffs, vesting charts, and investor pressure, not product usage or user growth.

And then, they’re bleeding tokens into a market that isn’t ready to catch them. 90% of token unlocks crash prices, even when 5% of the total supply is released. Meanwhile, over the next few months alone, scheduled unlocks will total around $9 billion.

Build the Business Plan First, Not the Tokenomics Last

The best token models start with the business. I mean a proper plan — the kind you’d pitch to a Series A investor and that forces you to map out what the company actually does, how it grows, where revenue comes from, and who benefits.

This clarity gives you the answers. Does this even need a token? Where does the token naturally plug into the product? What roles do users, validators, contributors, or liquidity providers play in creating demand?

Once that’s mapped, you can start modeling out the flow: who earns, who spends, who stakes, and when. Then you stress-test it: ‘What happens in a down market? What if usage explodes? How would fees, rewards, and emissions respond?’

Tools like Machinations can help you out here; so does walking through the model with someone who’s seen a hundred of them. But if the foundation is rotten, all the software and advice in the world won’t fix it.

If the Token’s Not Essential, Don’t Launch It Yet

Here’s what I tell every team: if your product can launch without a token, it probably should. Use equity, milestone-based SAFEs, or rev-share notes to fund early dev. When the product has traction — and there’s a clear role for the token in the loop — then you’re good to deploy.

Launching too early just invites speculation, so you end up spending the next two years defending a price chart instead of growing your user base.

On the other hand, when tokens are essential — e.g., powering blockspace fees, staking access to data feeds, or gating ecosystem rewards — their utility becomes the anchor. Demand grows with usage; the token is earned, spent, and recycled inside the product itself. That’s when emissions don’t destroy value, because you’ve got real activity behind it.

Take Solana: daily unlocks of roughly $14 million in tokens have weighed on its price, yet periods of strong network demand have repeatedly pulled it back up. Sui offers another case in point — after a January 1 unlock that released 64.19 million tokens (about $300 million), the token still surged nearly 28%, reaching a new all-time high of $5.1.

Founders Need to Design for Longevity, Not Launch Day

Founders love vesting cliffs and time-based unlocks — it’s simple, easy to model, and ticks the box for “long-term incentives.” Still, time alone isn’t a great signal. It’s way more efficient to tie unlocks to real milestones: number of active validators, modules shipped, usage targets hit; so the token supply would grow with the network.

Don’t build your model in a vacuum. Add slippage, bear markets, and team delays. If your model can’t survive those shocks, it’s not ready for launch.

And once you think it’s bulletproof, get someone to tear it apart. Experienced builders will spot the incentive flaws and edge cases your team’s too close to see.

Tokens Shape the Whole Market — So Build Accordingly

A lot of this comes down to mindset. If more founders treat token design as actual infrastructure — not cosmetic branding or a fundraising hack — we’d see better launches and stronger networks.

Venture investors are already starting to shift: the best of them focus on demand loops, not hype cycles. Exchanges are favoring transparency and sustainability over mystery unlocks and flash marketing. And regulators are more likely to respect a commodity-style utility token when it’s baked into usage, not just bolted on for optics.

Basically, it all boils down to this: if removing your token doesn’t break the loop, don’t launch. Build the loop first, then the token.

]]>
https://earlybirdsinvest.com/stop-treating-tokens-like-payday-buttons-theyre-infrastructure/feed/ 0 54781
Brain tech revolution: How new neural devices are treating depression and more https://earlybirdsinvest.com/brain-tech-revolution-how-new-neural-devices-are-treating-depression-and-more/ https://earlybirdsinvest.com/brain-tech-revolution-how-new-neural-devices-are-treating-depression-and-more/#respond Sat, 19 Jul 2025 17:06:03 +0000 https://earlybirdsinvest.com/brain-tech-revolution-how-new-neural-devices-are-treating-depression-and-more/

When you hear the word “neurotechnology,” you may picture Black Mirror headsets prying open the last private place we have — our own skulls — or the cyber-samurai of William Gibson’s Neuromancer. That dread is natural, but it can blind us to the real potential being realized in neurotech to address the long intractable medical challenges found in our brains. In just the past 18 months, brain tech has cleared three hurdles at once: smarter algorithms, shrunken hardware, and — most important — proof that people can feel the difference in their bodies and their moods.

A pacemaker for the brain

Keith Krehbiel has battled Parkinson’s disease for nearly a quarter-century. By 2020, as Nature recently reported, the tremors were winning — until neurosurgeons slipped Medtronic’s Percept device into his head. Unlike older deep-brain stimulators that carpet-bomb movement control regions in the brain with steady current, the Percept listens first. It hunts the beta-wave “bursts” in the brain that mark a Parkinson’s flare and then fires back millisecond by millisecond, an adaptive approach that mimics the way a cardiac pacemaker paces an arrhythmic heart.

In the ADAPT-PD study, patients like Krehbiel moved more smoothly, took fewer pills, and overwhelmingly preferred the adaptive mode to the regular one. Regulators on both sides of the Atlantic agreed: The system now has US and EU clearance.

Because the electrodes spark only when symptoms do, total energy use is reduced, increasing battery life and delaying the next skull-opening surgery. Better yet, because every Percept shipped since 2020 already has the sensing chip, the adaptive mode can be activated with a simple firmware push, the way you’d update your iPhone.

Scientists applied the same listen-then-zap logic farther down the spinal cord this year. In a Nature Medicine pilot, researchers in Pittsburgh laid two slender electrode strips over the sensory roots of the lumbar spine in three adults with spinal muscular atrophy. Gentle pulses “reawakened” half-dormant motor neurons: Every participant walked farther, tired less, and — astonishingly — one person strode from home to the lab without resting.

Half a world away, surgeons at Nankai University threaded a 50-micron-thick “stent-electrode” through a patient’s jugular vein, fanned it against the motor cortex, and paired it with a sleeve that twitched his arm muscles. No craniotomy, no ICU — just a quick catheter procedure that let a stroke survivor lift objects and move a cursor. High-tech rehab is inching toward outpatient care.

Mental-health care on your couch

The brain isn’t only wires and muscles; mood lives there, too. In March, the Food and Drug Administration tagged a visor-like headset from Pulvinar Neuro as a Breakthrough Device for major-depressive disorder. The unit drips alternating and direct currents while an onboard algorithm reads brain rhythms on the fly, and clinicians can tweak the recipe over the cloud. The technology offers a ray of hope for patients whose depression has resisted conventional treatments like drugs.

Thought cursors and synthetic voices

Cochlear implants for people with hearing loss once sounded like sci-fi; today more than 1 million people hear through them. That proof-of-scale has emboldened a new wave of brain-computer interfaces, including from Elon Musk’s startup Neuralink. The company’s first user, 30-year-old quadriplegic Noland Arbaugh, told Wired last year he now “multitasks constantly” with a thought-controlled cursor, clawing back some of the independence lost to a 2016 spinal-cord injury. Neuralink isn’t as far along as Musk often claims — Arbaugh’s device experienced some problems, with some threads detaching from the brain — but the promise is there.

On the speech front, new systems are decoding neural signals into text on a computer screen, or even synthesized voice. In 2023 researchers from Stanford and the University of California San Francisco installed brain implants in two women who had lost the ability to speak, and managing to hit decoding times of 62 and 78 words per minute, far faster than previous brain tech interfaces. That’s still much slower than the 160 words per minute of natural English speech, but more recent advances are getting closer to that rate.

Guardrails for gray matter

Yes, neurotech has a shadow. Brain signals could reveal a person’s mood, maybe even a voting preference. Europe’s new AI Act now treats “neuro-biometric categorization” — technologies that can classify individuals by biometric information, including brain data — as high-risk, demanding transparency and opt-outs, while the US BRAIN Initiative 2.0 is paying for open-source toolkits so anyone can pop the hood on the algorithms.

And remember the other risk: doing nothing. Refusing a proven therapy because it feels futuristic is a little like turning down antibiotics in 1925 because a drug that came from mold seemed weird.

Twentieth-century medicine tamed the chemistry of the body; 21st-century medicine is learning to tune the electrical symphony inside the skull. When it works, neurotech acts less like a hammer than a tuning fork — nudging each section back on pitch, then stepping aside so the music can play.

Real patients are walking farther, talking faster, and, in some cases, simply feeling like themselves again. The challenge now is to keep our fears proportional to the risks — and our imaginations wide enough to see the gains already in hand.

A version of this story originally appeared in the Good News newsletter. Sign up here!

]]>
https://earlybirdsinvest.com/brain-tech-revolution-how-new-neural-devices-are-treating-depression-and-more/feed/ 0 48553